Emergent BioSolutions | EBS - 净收入



金融业
股票价格
USD
资产
USD 1.82B
现金及等价物
USD 111.7M
销售成本
USD 381.2M
流动资产
USD 679.5M
流动负债
USD 651.3M
债务
USD 903.2M
股息收益率
0
EBIT
USD -148.1M
EBITDA
USD -113.5M
员工
1.6K
EPS每股收益
USD -0.77
股本和储备
USD 649.3M
销售毛利
USD 10M
债务利息支出
USD 17.9M
贷款资金
USD 446.5M
市值
USD 386.8M
净收入
USD -261.3M
营业费用
USD 555.9M
营业利润
USD -218M
普通股股本
USD 100K
PE价格收益
14.4
税前利润
USD -130.8M
销售收入
USD 276.6M
销售和管理费用
USD 182.8M
股票
USD 328.9M
贸易债权人
USD 112.2M
应收帐款人
USD 290.1M


净收入 更改 日
Acadia Pharmaceuticals USD 31.5M 27.86M 2026-06
Akebia Therapeutics USD -12.24M 12.78M 2025-12
ALKERMES USD 501K 66.98M 2026-06
Alnylam Pharmaceuticals USD 164.49M 41.5M 2026-06
Amarin USD -1.22M 6.51M 2025-12
ANI Pharmaceuticals USD 29.49M 2.86M 2026-03
BioMarin Pharmaceutical USD 105.53M 152.1M 2026-03
Coherus Biosciences USD -37.64M 2.11M 2025-12
Emergent BioSolutions USD -261.3M 78.3M 2023-06
Exelixis USD 210.47M 34.06M 2026-03
Glaxosmithkline GBP 1.74B 890.94M 2026-03
Heron Therapeutics USD -2.95M 14.54M 2025-12
Ionis Pharmaceuticals USD -114.65M 21.65M 2026-06
Ironwood Pharmaceuticals USD 3.19M 457K 2024-12
Lexicon Pharmaceuticals USD -15.53M 2.76M 2025-12
Lonza CHF 426M 119M 2025-06
Merck USD -1.34B 2.9B 2026-06
Moderna USD -1.34B 517M 2026-03
Myriad Genetics USD -7.9M 19.5M 2025-12
Nektar Therapeutics USD -44.9M 8.82M 2026-03
Neurocrine Biosciences USD 144.4M 53.5M 2026-06
Pacira USD 4.65M 1.74M 2026-06
Pfizer USD -248M 2.94B 2026-06
PTC Therapeutics USD -2.81M 132.16M 2026-03
Sanofi EUR 343M 1.27B 2026-06
Sarepta Therapeutics USD 330.96M 743.18M 2026-03
United Therapeutics USD 274.9M 89.4M 2026-03
Vanda Pharmaceuticals USD -18.9M 13.58M 2024-12